Coming Off a Compounded GLP-1: A Step-by-Step Transition Plan

The short version. Do not stop abruptly, do not assume your compounded dose maps one-to-one onto a brand pen, and do not treat this as a supply problem when it is really a planning opportunity. The six steps below are the order we work through with patients, and the order matters.

Where Things Actually Stand, Briefly

The short factual position, because the plan only makes sense against it. FDA determined the tirzepatide injection shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025. Enforcement discretion for compounding then ended on a published schedule: February 18, 2025 for 503A tirzepatide, March 19, 2025 for 503B tirzepatide, April 22, 2025 for 503A semaglutide, and May 22, 2025 for 503B semaglutide (FDA).

Separately, on April 30, 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List (FDA press announcement). That proposal published in the Federal Register on May 1, 2026, and the comment period was extended to July 30, 2026 (Federal Register, June 26, 2026). It is a proposal, not a completed rule: as of 17 August 2026 we could not confirm a final FDA determination. This area moves, so check the FDA pages linked above rather than relying on this paragraph in six months.

Step 1: Establish What You Are Actually Taking

This is first because it is the step most often skipped, and skipping it makes every later step guesswork.

Brand pens are calibrated in milligrams: you dial a dose. Compounded semaglutide has typically come as a multiple-dose vial at a pharmacy-chosen concentration, drawn with an insulin syringe marked in units. Many patients therefore know their dose in "units" and have never been told the milligram equivalent — and the milligram equivalent is the only number that transfers.

Write down three things before your appointment: the concentration in mg/mL printed on the vial, the volume you draw in millilitres, and the resulting dose in milligrams. Bring the vial and its label if you still have it.

This is not administrative tidiness. FDA's alert of July 26, 2024 documented patients instructed to draw a 5-unit (0.05 mL) dose who drew 50 units instead — a tenfold error — with prescriptions written for 25 units instead of 5, and 20 instead of 2. Some patients administered five to 20 times the intended dose and required medical attention or hospitalisation (FDA). A meaningful number of people are not on the dose they believe they are on, in both directions.

Step 2: Do Not Stop While You Sort This Out

The single most damaging response to a supply interruption is to stop and wait to see what happens.

According to PubMed, the STEP 1 trial extension followed participants for a year after once-weekly semaglutide 2.4 mg and lifestyle intervention were withdrawn. Mean weight loss on treatment had been 17.3 percent; one year after withdrawal participants had regained 11.6 percentage points of that loss, leaving a net 5.6 percent below baseline. Cardiometabolic improvements largely reverted toward baseline as well. The authors concluded that ongoing treatment is required to maintain the improvements (Wilding et al., Diabetes Obes Metab 2022, PMID 35441470, DOI).

Two things follow. First, obesity behaves as a chronic condition, and the response to withdrawal is a physiological one rather than a failure of willpower. Second, if stopping is genuinely the right decision for you — and sometimes it is, usually for cost — it should be a planned taper with structure built in advance, not an unplanned stop when the last vial runs out. That is step six.

Step 3: Recheck the Labs That Show What Treatment Achieved

A transition is the natural moment to find out what the medication has actually done for you, which the scale only partly answers.

We generally look at HbA1c, fasting insulin and glucose, a full lipid panel, liver enzymes, thyroid function and inflammatory markers, alongside body composition where available. Body composition matters more than people expect: preserving lean mass through a transition is a large part of whether your result holds.

This data does double duty. It guides the clinical decision, and it is the documentation that supports an insurance prior authorization or appeal if you need one.

Step 4: Map Your Real Options, With Real Numbers

There are more paths than "pay full price or quit", and they are worth laying out side by side before deciding:

• Switch to the approved product for the same molecule, pursuing insurance coverage where a qualifying indication exists.
• Switch molecules where clinically sensible — coverage and access sometimes differ between semaglutide and tirzepatide products even when the clinical case is similar.
• Manufacturer self-pay channels, which have changed materially since 2025 and are worth checking directly rather than assuming. Current figures and sourcing are covered in compounded vs brand semaglutide; verify pricing with the manufacturer before budgeting, since these programmes change frequently.
• A planned, structured step down if continuing is not financially sustainable.

What we will not do is engineer a workaround for a regulatory position. If a route is not available, we will say so plainly rather than pointing you somewhere unregulated. Anything sold without a prescription, labelled "for research use only", or requiring you to reconstitute powder yourself sits outside the legitimate supply chain, and FDA has warned about exactly that pattern.

Step 5: Titrate Deliberately — Do Not Assume Dose Equivalence

The assumption that a given milligram dose of a compounded preparation maps precisely onto the same milligram dose of an approved product is the assumption that produces avoidable nausea in week one.

In practice, once the true milligram dose from step one is established, we commonly restart a step below it and retitrate over roughly four to six weeks against appetite control and tolerability. That is usually a small delay in exchange for a far smoother month, and it substantially reduces the chance of someone abandoning a treatment that was working because the first fortnight was miserable.

Expect closer contact during this window — roughly fortnightly while the dose is moving, spacing out once you are stable.

Step 6: Build the Maintenance Floor Before You Need It

Whether you are continuing on an approved product or stepping down, the habits that protect your result should be in place before the transition, not improvised after regain has started.

Concretely, that means a protein target you actually hit daily, resistance training at least twice a week to defend lean mass, sleep treated as part of the protocol rather than an afterthought, and a monitoring interval booked in the calendar rather than left to whenever something feels wrong.

What I see in clinic: the people who transition smoothly are almost always the ones who started this step a month early. The ones who struggle are usually the ones who waited to see whether they would need it.

What This Looks Like as a Consultation

The first visit covers your current regimen in real numbers, your dosing history and side effects, your weight and lab trends, and your insurance position. Labs are typically ordered before or during that visit, with results back within about a week.

Most people leave with a written transition plan: medication options with their costs, a dosing schedule, and monitoring intervals. Follow-up runs at roughly two-week intervals through the transition, then settles into a longer cycle with periodic metabolic labs once you are stable.

The consultation is $35, applied toward your treatment plan if you proceed.

Frequently Asked Questions

My supply ends this month. What do I do first?

Establish your true dose in milligrams, and book a review before your last dose rather than after it. Those two things in that order prevent most of the avoidable problems.

Can I just stop and restart later when I can afford it?

You can, but understand what the data show. In the STEP 1 extension, participants regained roughly two-thirds of their lost weight in the year after withdrawal, with cardiometabolic markers largely reverting toward baseline (PMID 35441470, DOI). If cost means stopping, plan the stop rather than letting it happen to you.

Is my compounded dose the same as the brand dose?

Not reliably, and it should not be assumed. Establish the milligram dose from the vial concentration and the volume you draw, then retitrate deliberately rather than transferring the number across.

Can I still get a compounded version?

The broad, shortage-based permission ended in 2025 on the schedule above. Compounding for a documented individual clinical need that the approved product cannot meet is a narrow and separate question, and a clinical determination rather than a preference. Cost alone does not create that need.

Will I get side effects again when I switch?

Most people do not. A minority get mild, temporary nausea in the first week or two, which is usually resolved by escalating the dose more slowly — which is precisely why step five is deliberate rather than fast.

What if my insurance denies coverage?

Denials are frequently appealable with proper clinical documentation, which is one of the reasons step three comes before step four. We prepare that documentation and handle prior authorisations and appeals where coverage is plausible.

Could compounding become permitted again?

It could, if a genuine shortage were declared again — that is how the mechanism works. The April 2026 proposal would close the separate 503B bulks pathway permanently if finalised; we could not confirm a final determination as of 17 August 2026.

Talking It Through in Ann Arbor

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner. We are at 2217 Packard St #15, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters and no parking structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before your visit so we can make arrangements.

Call (734) 436-3357 or book your first visit. The consultation is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted.

References

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470. doi:10.1111/dom.14725
2. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
3. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B Bulks List, April 30, 2026.
4. Federal Register. List of bulk drug substances for which there is a clinical need under section 503B; extension of comment period, June 26, 2026.
5. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded semaglutide injectable products, July 26, 2024.

Clinical information on this page is drawn from articles retrieved from PubMed and from primary FDA sources, and is provided for education. It is not medical advice, not legal advice, not a diagnosis, and not a promise of any individual result. Regulatory status reflects sources verified on 17 August 2026 and may have changed since.